Home > Cardiology > ESC 2021 > 2021 ESC Clinical Practice Guidelines > 2021 ESC Guidelines on Heart Failure

2021 ESC Guidelines on Heart Failure

Presented By
Prof. Carolyn Lam, Duke-NUS Medical School, Singapore
ESC 2021
Substantial revisions have been made by the Task Force for the diagnosis and treatment of acute and chronic heart failure (HF) of the European Society of Cardiology (ESC). Among them, an indication for SGLT2 inhibitors for all HF patients with reduced ejection fraction (HFrEF) and the introduction of the new phenotype of HF with mildly reduced EF (HFmrEF). After 5 years and with the emergence of abundant valuable evidence, the 2021 ESC Guidelines on HF comprise major changes to those published in 2016. Where overlapping, guidelines were harmonised. The new recommendations, which include a multitude of treatment modifications, have also redefined a phenotype from HF with mid-range EF to HF with mildly reduced EF as a new concept [1]. “After the diagnosis of heart failure is confirmed, the guidelines recommend classification by left ventricular (LV) EF into those with a reduced EF of 40% or less, those with a mildly reduced EF above 40% but less than 50%, an...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on